研究单位：[1]Tasly Pharmaceutical Group Co., Ltd[2]Capital Medical University Affiliated Anding Hospital,Beijing,Beijing,China[3]Peking University Sixth Hospital,Peking,Beijing,China[4]Chongqing 11th People''s Hospital,Chongqing,Chongqing,China[5]Chongqing Mental Health Center,Chongqing,Chongqing,China[6]The Affiliated Brain Hospital of Guangzhou Medical University,Guangzhou,Guangdong,China[7]Hebei Provincial Mental Health Center,Baoding,Hebei,China[8]The First Hospital of Hebei Medical University,Shijiazhuang,Hebei,China[9]Daqing Third Hospital,Daqing,Heilongjiang,China[10]Wuxi Mental Health Center,Wuxi,Jiangsu,China[11]Zhenjiang Mental Health Center,Zhenjiang,Jiangsu,China[12]Jiangxi Provincial Psychiatric Hospital,Nanchang,Jiangxi,China[13]Jilin Provincial Neuropsychiatric Hospital,Siping,Jilin,China[14]Shandong Provincial Mental Health Center,Jinan,Shandong,China[15]Tianjin Anding Hospital,Tianjin,Tianjin,China[16]Ürümqi Fourth People''s Hospital,Ürümqi,Xinjiang,China[17]The First Affiliated Hospital of Kunming Medical University,Kunming,Yunnan,China[18]Huzhou Third People''s Hospital,Huzhou,Zhejiang,China
研究目的：
The purpose of this study is to evaluate the Effectiveness and Safety of JS1-1-01 in Patients With Moderate to Severe Depression
